Theravance Biopharma is part of the biotechnology industry and is part of the healthcare sector. The company CEO is Rick E. Winningham. Theravance Biopharma Inc is a diversified biopharmaceutical company. It is engaged in discovery, research, development and commercialization of human therapeutics.



Previous Intraday Performance:

The TBPH shares had a previous change of 2.95% which opened at 16.40 and closed at 16.76. It moved to an intraday high of 17.00 and a low of 16.10.

PR Newswire:  Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories

Historical Performance:

Over the last five trading days, TBPH shares returned 6.82% and in the past 30 trading days it returned -33.36%. Over three months, it changed -26.72%. In one year it has changed -29.55% and within that year its 52 week high was 35.48 and its 52 week low was 15.18. TBPH stock is 10.41% above its 52 week low.

Our calculations result in a 200 day moving average of 25.21 and a 50 day moving average of 21.00. Right now, TBPH stock is trading -33.53% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Theravance Biopharma appoints new finance chief

Liquidity:

The company has a market cap of $940.9m with 56.1m shares outstanding and a float of 51.8m shares. Trading volume was 335,824 shares and has experienced an average volume of 347,110 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Theravance Biopharma was -4 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -1.18.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-07-2019: -1.32
4thQtr 2018Reported 02-26-2019: -0.92
3rdQtr 2018Reported 11-06-2018: -1.10
2ndQtr 2018Reported 08-01-2018: -0.76
1stQtr 2018Reported 05-08-2018: -1.22

The long-term trend of the EPS is an important number as it indicates the present value of Theravance Biopharma; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 172.00% over the last twelve months.

Indicators Also to Watch:

The beta was calculated to be 1.82.



PR Newswire:  Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -46.05%, price-to-sales is 15.92 and price-to-book is 39.11.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 3  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here